about
Immune Dysfunction as a Cause and Consequence of MalnutritionRotavirus-associated mild encephalopathy with a reversible splenial lesion (MERS)-case report and review of the literatureThe impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trialsHIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination.Cytomegalovirus Acquisition and Inflammation in Human Immunodeficiency Virus-Exposed Uninfected Zimbabwean Infants.Head circumferences of children born to HIV-infected and HIV-uninfected mothers in Zimbabwe during the preantiretroviral therapy eraHIV-Exposed Uninfected Infants in Zimbabwe: Insights into Health Outcomes in the Pre-Antiretroviral Therapy Era.Aflatoxin Exposure During Pregnancy, Maternal Anemia, and Adverse Birth Outcomes.Immunity to HIV in Early LifeThe stunting syndrome in developing countries.A randomized trial of prolonged co-trimoxazole in HIV-infected children in AfricaCongenital and postnatal CMV and EBV acquisition in HIV-infected Zimbabwean infantsStunting is characterized by chronic inflammation in Zimbabwean infantsPubertal development in HIV-infected African children on first-line antiretroviral therapy.Acute illness is associated with suppression of the growth hormone axis in Zimbabwean infants.T-Cell Subsets Predict Mortality in Malnourished Zambian Adults Initiating Antiretroviral Therapy.Linear growth faltering in infants is associated with Acidaminococcus sp. and community-level changes in the gut microbiotaAssessment of Environmental Enteric Dysfunction in the SHINE Trial: Methods and Challenges.Assessing the Intestinal Microbiota in the SHINE Trial.Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions.The Potential Role of Mycotoxins as a Contributor to Stunting in the SHINE Trial.Formative research on hygiene behaviors and geophagy among infants and young children and implications of exposure to fecal bacteriaLinear growth trajectories in Zimbabwean infantsInteractions between zinc deficiency and environmental enteropathy in developing countries.Dosing of praziquantel by height in sub-Saharan African adultsEarly infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review.HIV and the Millennium Development Goals.The expanding role of co-trimoxazole in developing countries.Malnutrition and vaccination in developing countries.Determinants of recent aflatoxin exposure among pregnant women in rural Zimbabwe.Interactions between intestinal pathogens, enteropathy and malnutrition in developing countriesReduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.Impaired Barrier Function and Autoantibody Generation in Malnutrition Enteropathy in Zambia.Child Growth According to Maternal and Child HIV Status in ZimbabweThe impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysisStunting Persists despite Optimal Feeding: Are Toilets Part of the Solution?Chronic meningitis with intracranial hypertension and bilateral neuroretinitis following Mycoplasma pneumoniae infection.Role of HIV-specific CD8(+) T cells in pediatric HIV cure strategies after widespread early viral escape.Intestinal Damage and Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Zimbabwean Infants.
P50
Q26745474-6214CA59-1218-4AAF-A201-64F345C17A72Q26779370-3A30DD82-885C-4B03-82F6-3F2D5D1C7248Q28660009-7AE83234-C2A7-413E-B1A9-8FC007E7D16BQ30062047-569B39E3-4AEF-40D9-8367-5F01E8047DC2Q30377601-C4ABAB9C-6204-4DA7-8780-080CD7C1D201Q30381646-D3692847-6460-4537-8935-7C281CD09138Q30383065-815396B0-7865-4717-B683-C298AFC5C75CQ33567766-79706E18-DF75-42E7-A9AD-8E676934FFFCQ34033051-98B431B1-9EF7-4605-84CE-F0430878DAA8Q34443195-CCB1C869-9409-473E-912D-A6C140C72862Q34687538-D2A45A4B-5F3A-44E5-9C15-CC987B360F48Q34734281-DA7F873F-51B2-40BD-98AF-E91A22BB4BC8Q35099463-B2B2E5A6-64F0-43CA-9AFC-68A26EB2D979Q35126455-791A744A-02B8-4D5B-B7F3-69FC2C4B5B1FQ35140513-C16CFF53-5E49-46CE-AAE9-E844363357CAQ35666026-073CE3E5-9B76-4653-A5F1-0EC31AE0B72BQ35770107-B07A4601-A0C6-4EEA-8438-1B29E004E458Q35851350-29C8FEE8-912E-424B-A1A9-ED362ED823B1Q35851354-CC2C9EBC-DB25-4724-8911-EFCE33AC727FQ36092315-26E51FCC-81A0-40CE-A095-99938C8957E8Q36311606-D76716EF-F5BB-4B0C-9D84-1A6672DDD93AQ37225789-0F1413AC-6A48-483C-ABC4-720644DE77BBQ37428096-0A9F2622-295F-41B8-B63C-D1A147764C4FQ37446572-E95A498F-7066-4789-92B1-1610E3AD9414Q37680701-9270EA29-079E-41B0-9DF9-B00194466F42Q38181250-41DF6773-9912-4AC3-A9FD-76DA309A74D0Q38213575-83516469-0BE0-4C12-8840-7E772D9D8541Q38329372-D01E2A97-AAFF-461A-BD7A-8A1E1DE95E2EQ38330997-88CC887D-E324-4A85-887D-BD13FE7BE8C3Q38474417-D17A9E61-BFA0-4FD5-AD1C-9159DA3AC64FQ38763672-E89AE9FA-4A64-4F94-9AAC-A31FBDD08E09Q38769846-119E27AC-687E-4C5B-9958-617B18EDBE37Q38852917-994445FA-7F1F-4F1D-96EE-0A365586B42AQ38871793-196D53E4-4B49-40DC-8D87-F6BE83E8A153Q38960638-FD7AB9B9-623B-4C4D-BC18-47FE53446FE0Q39003366-AA7B6D03-3DEF-44A2-906A-E554BC20DF11Q41139865-4894F877-3E1F-4EE5-8E07-68F82A70EE88Q41583259-0ABB0EB2-EFA4-45A5-BC2B-BEB2B5AAFFC1Q41923263-9AB9BC8D-3F75-4B10-80AB-12434260398AQ41932805-9D300F05-D667-4001-8BEA-0AB8142D6DDF
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Andrew Prendergast
@en
Andrew Prendergast
@nl
type
label
Andrew Prendergast
@en
Andrew Prendergast
@nl
prefLabel
Andrew Prendergast
@en
Andrew Prendergast
@nl
P31
P496
0000-0001-7904-7992